BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025
BioCardia (NASDAQ:BCDA), a company focused on developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, will host its Q2 2025 earnings conference call on August 11, 2025 at 4:30 PM ET.
The company will provide a corporate update and discuss financial results for the quarter ended June 30, 2025. The call will include management remarks followed by a Q&A session. Participants can join through a dial-in number after registration or via webcast.
BioCardia (NASDAQ:BCDA), un'azienda specializzata nello sviluppo di terapie cellulari e derivate per malattie cardiovascolari e polmonari, terrà la sua conference call sui risultati del secondo trimestre 2025 l'11 agosto 2025 alle 16:30 ET.
L'azienda fornirà un aggiornamento aziendale e discuterà i risultati finanziari relativi al trimestre conclusosi il 30 giugno 2025. La chiamata includerà interventi del management seguiti da una sessione di domande e risposte. I partecipanti potranno accedere tramite un numero telefonico dopo la registrazione o tramite webcast.
BioCardia (NASDAQ:BCDA), una empresa enfocada en el desarrollo de terapias celulares y derivadas para enfermedades cardiovasculares y pulmonares, llevará a cabo su conferencia telefónica de resultados del segundo trimestre de 2025 el 11 de agosto de 2025 a las 4:30 PM ET.
La compañía proporcionará una actualización corporativa y discutirá los resultados financieros del trimestre finalizado el 30 de junio de 2025. La llamada incluirá comentarios de la dirección seguidos de una sesión de preguntas y respuestas. Los participantes podrán unirse mediante un número telefónico tras registrarse o a través de una transmisión web.
BioCardia (NASDAQ:BCDA)는 심혈관 및 폐 질환을 위한 세포 및 세포 유래 치료제 개발에 주력하는 회사로, 2025년 8월 11일 오후 4시 30분(동부시간)에 2025년 2분기 실적 컨퍼런스 콜을 개최합니다.
회사는 기업 현황 업데이트와 2025년 6월 30일로 종료된 분기의 재무 결과를 발표할 예정입니다. 콜에는 경영진의 발언과 이어서 질의응답 시간이 포함됩니다. 참가자는 등록 후 전화 접속 번호를 통해 또는 웹캐스트로 참여할 수 있습니다.
BioCardia (NASDAQ:BCDA), une entreprise spécialisée dans le développement de thérapies cellulaires et dérivées pour les maladies cardiovasculaires et pulmonaires, tiendra sa conférence téléphonique sur les résultats du deuxième trimestre 2025 le 11 août 2025 à 16h30 ET.
L'entreprise fournira une mise à jour corporative et discutera des résultats financiers pour le trimestre clos au 30 juin 2025. L’appel comprendra des remarques de la direction suivies d’une session de questions-réponses. Les participants pourront rejoindre la conférence via un numéro d’appel après inscription ou par webcast.
BioCardia (NASDAQ:BCDA), ein Unternehmen, das sich auf die Entwicklung von zellbasierten und zellabgeleiteten Therapeutika für Herz-Kreislauf- und Lungenerkrankungen spezialisiert hat, wird seine Telefonkonferenz zu den Ergebnissen des zweiten Quartals 2025 am 11. August 2025 um 16:30 Uhr ET abhalten.
Das Unternehmen wird ein Unternehmensupdate geben und die Finanzergebnisse für das am 30. Juni 2025 endende Quartal besprechen. Die Konferenz umfasst Ansprachen des Managements, gefolgt von einer Fragerunde. Teilnehmer können nach Registrierung über eine Einwahlnummer oder per Webcast teilnehmen.
- None.
- None.
SUNNYVALE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three months ended June 30, 2025 by conference call on Monday, August 11, 2025 at 4:30 PM ET. Following management’s formal remarks, there will be a question-and-answer session.
Participants can register for the conference by navigating to https://dpregister.com/sreg/10201553/ff96e5f036. Please note that registered participants will receive their dial-in number upon registration. For those who have not registered, to listen to the call by phone, interested parties within the U.S. should call 1-833-316-0559 and international callers should call 1-412-317-5730. All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the BioCardia call. The conference call will also be available through a live webcast, which can be accessed through the following link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=ZDm6XgM2.
A webcast replay of the call will be available approximately one hour after the end of the call at the above links. A telephonic replay of the call will be available and may be accessed by calling 1-877-344-7529 (domestic), 1-412-317-0088 (international) or 855-669-9658 (Canada) by using access code 7650783.
About BioCardia®
BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph® vascular navigation product platforms. For more information visit www.biocardia.com.
MEDIA CONTACT: Miranda Peto, Marketing / Investor Relations mpeto@biocardia.com (650) 226-0120 INVESTOR CONTACT: David McClung, Chief Financial Officer investors@biocardia.com (650) 226-0120
FAQ
When is BioCardia's (BCDA) Q2 2025 earnings call?
How can investors join BioCardia's Q2 2025 earnings call?
What will be discussed in BioCardia's Q2 2025 earnings call?
What is BioCardia's (BCDA) main business focus?
